Delusions clinical trials
The registry lists 32 studies for Delusions across more than 10 countries. 8 are recruiting or about to start. 3 of them are mainly about Delusions (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05.
Get an email when these change. Save the Delusions studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
ACADIA Pharmaceuticals Inc. (4) · National Institute of Mental Health (NIMH) (2) · Philipps University Marburg (2) · Weill Medical College of Cornell University (2) · New York State Psychiatric Institute (2) · MapLight Therapeutics (2) · Alexandria University (1) · The University of Texas Health Science Center at San Antonio (1)
What is being tested here
Drugs under test in Delusions studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Remlifanserin | 2 | 2 | 2 |
| ML-007C | 2 | 0 | 2 |
| Pimavanserin | 1 | 1 | 4 |
| Quetiapine | 1 | 0 | 1 |
| Lithium | 0 | 0 | 1 |
| Aqw-051 | 0 | 0 | 1 |
| Cycloserine | 0 | 0 | 1 |
| Eicosapentaenoic acid ethyl ester | 0 | 1 | 1 |
Drug classes tested here Antipsychotics 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 6 Delusions studies recruiting now, 1 (17%) set no upper age limit and 3 (50%) stop at 75 or younger. 1 (17%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (17%) | 1 (17%) |
| 18 | 4 (67%) | 4 (67%) |
| 30 | 4 (67%) | 4 (67%) |
| 40 | 4 (67%) | 4 (67%) |
| 50 | 3 (50%) | 3 (50%) |
| 65 | 5 (83%) | 5 (83%) |
| 75 | 3 (50%) | 3 (50%) |
| 85 | 3 (50%) | 3 (50%) |
Across all 32 studies, recruiting or not: 56% stop at 75 or younger and 47% at 65; 19% take children; 3% are for women only and 3% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 32 of 32. search them.
- ACP-204 in Adults With Alzheimer's Disease PsychosisRecruitingNCT06159673Phase 2/312 countries
- ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension StudyEnrolling by invitationNCT06194799Phase 312 countries
- A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRecruitingNCT06887192Phase 215 countries
- Volatility in Paranoia (VIP) Trial: An RCT of Changes in Volatility With PsychotherapyRecruitingNCT06835556Not applicable1 country
- An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease PsychosisEnrolling by invitationNCT07459660Phase 23 countries
- Comparing Antipsychotic Medications in LBD Over TimeRecruitingNCT05590637Phase 41 country
- Delusion Ideation in the Context of Everyday LifeRecruitingNCT06207526Not applicable1 country
- Metacognitive Training as a Serious GameRecruitingNCT04631939Not applicable2 countries
- Genetic Study of SchizophreniaCompletedNCT000014861 country
- Face Your Fears: Cognitive Behavioural Virtual Reality Therapy for "Paranoia".CompletedNCT04902066Not applicable1 country
- Pimavanserin for Sleep in Parkinson DiseaseWithdrawnNCT05796167Early Phase 11 country
- Treatment of Psychosis and Agitation in Alzheimer's DiseaseCompletedNCT02129348Phase 21 country
- Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)CompletedNCT052403391 country
- Effect of Applying Cognitive Defusion Techniques on Mindful Awareness, Cognitive Fusion and Believability of Delusions Among Clients With SchizophreniaCompletedNCT05759091Not applicable1 country
- Intervention to Improve Coping With Negative Emotions in Patients With Psychosis (Feel-Good-Study)CompletedNCT04592042Early Phase 11 country
- Relapse Prevention Study of Pimavanserin in Dementia-related PsychosisCompletedNCT03325556Phase 313 countries
- Enhancement of Treatment of Delusions in Schizophrenia Through NeuromodulationWithdrawnNCT03062553Not applicable1 country
- Effect of AQW051 on Cognitive Function in Patients With Chronic Stable SchizophreniaCompletedNCT01163227Phase 21 country
- D-Cycloserine Augmentation of Cognitive Behavioral Therapy for DelusionsCompletedNCT01981759Phase 41 country
- Efficacy and Mechanisms of Change of an Emotion-oriented Version of Cognitive-behavioral Therapy for PsychosisCompletedNCT02787135Not applicable1 country
- Effect of 4-session Metacognitive Training in Chinese Adult Outpatients With Schizophrenia Spectrum Disorders and Major Depressive DisorderCompletedNCT03449394Not applicable1 country
- Cognitive Behavioral Therapy for Paranoia in SchizophreniaCompletedNCT01704833Not applicable1 country
- Study the Effects of Vitamin D and Calcium Supplementation at Tolerable Upper Limit Doses on Calcium Metabolism.CompletedNCT02019381Not applicable1 country
- Self Directed Positive Parenting Program (Triple P) for Psychosis: A Clinical Case SeriesCompletedNCT02199704Not applicable1 country
- CATIE-Alzheimer's Disease TrialCompletedNCT00015548Not applicable1 country
- Metacognitive Training in SchizophreniaCompletedNCT01029067Not applicable1 country
- Treating Behavioral Disturbances in Individuals With DementiaCompletedNCT00073658Phase 21 country
- Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral TherapyCompletedNCT00791440Not applicable1 country
- Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of SchizophreniaCompletedNCT01176721Phase 21 country
- Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and AntioxidantsCompletedNCT00419146Phase 2/31 country
- Acceptance and Commitment Therapy for DelusionsCompletedNCT00657631Not applicable1 country
- Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and RisperidoneCompletedNCT00361166Phase 22 countries